GSK, Sanofi and Haleon shares slump on Zantac litigation concerns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Sanofi (SNY) Knee Jerk Reaction 'Overdone' - Deutsche Bank
August 12, 2022 11:34 AM EDTShares of Sanofi (NASDAQ: SNY) were upgraded to Hold from Sell with an unchanged EUR90 price target by Deutsche Bank analyst Emmanuel Papadakis on Friday.
Sanofi shares have tumbled in recent days on worries surrounding litigation around recalled heartburn drug Zantac.... More
Why GSK and Sanofi Shares are Trading Sharply Lower This Week
August 11, 2022 8:44 AM EDTShares of GSK (NYSE: GSK), formerly GlaxoSmithKline, are down over 8% in premarket Thursday amid mounting concerns about the recalled drug Zantac.
The company is facing lawsuits as it allegedly failed to warn users about the over-the-counter products health risks. Zantac was a popular drug that was recalled since it... More
Deutsche Bank Sees Short Term Zantac Headwind for Sanofi (SNY) and Glaxo (GSK): 'we may see a liability of some $bn magnitude incurred'
August 11, 2022 8:16 AM EDTDeutsche Bank analyst Emmanuel Papadakis comments "We were holding our pen on this topic pending a detailed review of the subject: whilst that still remains a work in progress, the stock price moves the topic has triggered necessitate a very brief comment. The summary is that this topic is... More
